{"organizations": [], "uuid": "0f5e1ea80aa276a220e9ab7dec6f45a37cf0efa2", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180122.html", "section_title": "Archive News &amp; Video for Monday, 22 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nanobiotix-presents-data-from-phas/brief-nanobiotix-presents-data-from-phase-i-ii-liver-cancers-trial-of-nbtxr3-idUSFWN1PH03O", "country": "US", "domain_rank": 408, "title": "BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T15:32:00.000+02:00", "replies_count": 0, "uuid": "0f5e1ea80aa276a220e9ab7dec6f45a37cf0efa2"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nanobiotix-presents-data-from-phas/brief-nanobiotix-presents-data-from-phase-i-ii-liver-cancers-trial-of-nbtxr3-idUSFWN1PH03O", "ord_in_thread": 0, "title": "BRIEF-Nanobiotix Presents Data From Phase I/II Liver Cancers Trial Of NBTXR3", "locations": [], "entities": {"persons": [{"name": "nanobiotix", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 22 (Reuters) - NANOBIOTIX SA:\n* NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING\n* VERY GOOD SAFETY PROFILE WITH NO AES AND SAES RELATED TO NBTXR3\n* THIRD INDICATION IN GLOBAL NBTXR3 DEVELOPMENT CONFIRMING TRANSFERABILITY ACROSS DIFFERENT CANCERS\n* ‍COMPLETE RESPONSE ACHIEVED IN 3 OUT OF 7 PATIENTS EVALUABLE​\n* ‍PARTIAL RESPONSE ACHIEVED IN 3 OUT OF 7 Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-22T15:32:00.000+02:00", "crawled": "2018-01-23T18:08:13.000+02:00", "highlightTitle": ""}